Niastase Rt 5 mg (Eptacog Alfa (Activated) KIT) 5 MG

Niaspase RT 5 mg is a pharmaceutical kit containing eptacog alfa (activated) for intravenous use. This medication is designed to support clotting processes in the body. Learn more about its uses and effects.

Strength

5 MG

Manufacturer / TM Owner

NOVO NORDISK CANADA INC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Niaspase RT 5 mg is generally used to manage bleeding episodes in patients with certain clotting disorders. Eptacog alfa (activated) works by promoting the formation of blood clots. This medication is often considered when other treatments are not effective or suitable. Always consult a healthcare provider to determine if this medication is appropriate for your specific condition.

Side Effects

Common effects of Niaspase RT 5 mg may include localized reactions at the injection site, such as redness or swelling. Some users might experience mild to moderate discomfort during administration. Severe side effects are rare but should be reported to a healthcare professional immediately.

Precautions & Warnings

Niaspase RT 5 mg should be handled with care, following the instructions provided by your healthcare provider. Ensure the medication is stored properly and administered by a trained professional. Always inform your healthcare provider about any allergies or medical conditions before using this medication.

Avoid Interactions

Niaspase RT 5 mg may interact with other medications, particularly those that affect blood clotting. It is important to discuss all current medications with your healthcare provider to avoid potential interactions. Alcohol and certain supplements may also impact the effectiveness of this medication.

Frequently Asked Questions

Niaspase RT 5 mg is typically used to manage bleeding episodes in patients with certain clotting disorders.

Niaspase RT 5 mg is administered intravenously, usually by a healthcare professional.

Common side effects may include localized reactions at the injection site, such as redness or swelling.

It is important to discuss all current medications with your healthcare provider to avoid potential interactions.

Niaspase RT 5 mg should be stored according to the instructions provided by your healthcare provider.

Editorial & Trust Signals

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical wholesaler & exporter

Last updated: 17 Jun 2026

References

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.